A b s t r a c t Venous thromboembolism (VTE) results from the interaction of the Virchow triad (venous stasis, endothelial injury, and hypercoagulability
Case Scenario
A 46-year-old Caucasian man was admitted for newonset hemoptysis, dyspnea on exertion, and bilateral chest pain. He had been discharged 2 weeks previously after an 8-day stay for trauma when a bulldozer rolled off a trailer and hit him. He had fractures of the right arm, right ribs, and both cervical and thoracic vertebrae, requiring surgery. He has been using oxycodone while an outpatient. His vital signs were significant for tachycardia and an oxygen saturation of 91% while breathing room air. Examination revealed rales at both lung bases, clean surgical wounds, and no evidence of lower extremity tenderness, cords, or edema. Chest computed tomography with contrast showed a pulmonary embolism in the right lower lobe. Doppler ultrasounds of the extremities were negative. He had a normal CBC, prothrombin time (PT), and partial thromboplastin time (PTT), but a D-dimer level 5 times the upper limit of the reference range. Protein C and S activities were ordered 2 days after starting intravenous unfractionated heparin and after 2 doses of warfarin. The clinical pathologist was consulted on whether the patient should be further evaluated for thrombophilia. There was no personal or family history of thrombosis; his mother and sister had first-trimester miscarriages.
Background
Thrombophilia is the increased tendency to venous thromboembolism (VTE) due to predisposing congenital and/or acquired factors. VTE affects approximately 1 to 2 people per Upon completion of this activity you will be able to:
• list the inherited risk factors for thrombosis that can be tested in the laboratory.
• discuss why testing for thrombophilia risk factors is often affected by the patient's underlying clinical condition.
• apply the concepts from this review when providing consultation to clinicians.
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1,000 in the Western general population 1 ; in the United States, more than 900,000 people annually have VTE, with about 300,000 deaths and a higher number surviving with complications. 2 VTE has a recurrence risk of about 30%. 3 Treatment goals include effective risk stratification for recurrence, prophylaxis, and modification of risk factors to improve survival and prevent complications. The Virchow triad of venous stasis, vascular endothelial injury, and intrinsic alterations in the coagulation nature of the blood itself inform this risk assessment. 4 Such "blood alterations" have become the thrombophilias that may be circumstantial, disease-related, or inherited.
Questions
• What are the most prevalent inherited and acquired risk factors for VTE? • Which patients should be considered for thrombophilia testing? • What preanalytic variables and conditions should be considered for a thrombophilia investigation? • How does thrombophilia testing affect VTE treatment?
Congenital Thrombophilias
Well-defined VTE risk factors include resistance to activated protein C (APCR) due to factor V Leiden (FVL), prothrombin G20210A gene mutation (P20210), high factor VIII (FVIII) activity or homocysteine level, and natural anticoagulant deficiencies: antithrombin (AT), protein C (PC), and protein S (PS). Patients with laboratory-confirmed thrombophilia are at greater risk for VTE, but most will never have an event. 5 VTE risk increases synergistically as other risk conditions are acquired (eg, pregnancy, trauma, immobilization). More than 60% of patients with idiopathic (spontaneous or unprovoked) VTE have inherited thrombophilia 6 ; abnormal APCR, a negative workup, and P20210 were found in 33%, 32%, and 18% of patients, respectively.
Acquired Thrombophilia
Circumstantial risk factors for VTE include age older than 50 years, previous thrombosis, exogenous estrogens, prolonged immobilization (eg, transoceanic plane travel, bed rest >3 days, nonambulatory states, plaster casting), orthopedic surgery (especially knee and hip replacement), chronic inflammation, and malignancy. 7 Risk factors must be considered during examination of patients with VTE, and a complete "thrombotic medical and family history" must be taken. 8 Antiphospholipid syndrome (APS) is an important cause of acquired thrombophilia diagnosed in the laboratory that can also cause arterial thrombosis and recurrent fetal loss. 9 
Laboratory Investigation Guidelines
Evidence-based guidelines recommend laboratory evaluation for thrombophilia only for selected patient populations ❚Figure 1❚. [10] [11] [12] [13] [14] Testing should encompass all risk factors because combined defects are common (unless clinical conditions interfere with test interpretation). If high-priority tests are negative, low priority studies (eg, dysfibrinogenemia testing or factor IX and XI activity) should be considered. 14 Unique circumstances can dictate the workup; unexplained intra-abdominal VTE (portal, splenic, mesenteric, or hepatic) suggests the need for JAK2 mutation testing and flow cytometric CD55/CD59/fluorescent aerolysin expression in blood cells to evaluate for myeloproliferative disorders and paroxysmal nocturnal hemoglobinuria, respectively. 15, 16 Laboratory Evaluation
APCR/FVL
The FVL point mutation (G1691A) renders the first factor V cleavage site more resistant to the APC/PS complex, hence APCR. Up to 8% of Caucasians in the United States are heterozygous for FVL, and 1 in 5,000 are homozygous. FVL occurs more rarely in African Americans and people of Hispanic or Arabic descent. FVL heterozygotes have a 3-to 7-fold and homozygotes an 80-fold increased risk of VTE; a second risk factor (oral contraceptives, pregnancy, PS deficiency) in a FVL heterozygous person synergistically increases the risk of VTE. 11 Most laboratories use a strategy to first screen for APCR with the second-generation (V-deficient) test. If the APCR result is abnormal, genotyping for FVL is reflexively performed. 17 DNA analysis alone would not identify acquired APCR (such as lupus anticoagulant [LA]) or rare factor V mutations that can also cause APCR. 18 
Prothrombin G20210A
P20210 is the second most prevalent inherited VTE risk factor, resulting in an increased concentration of functional prothrombin and, subsequently, the generation of more thrombin. P20210 is present in approximately 2% to 3% of Caucasians, Hispanics, and Arabs but is rare in Africans and Asians. P20210 occurs in 6% to 8% of all patients with VTE and 18% of patients with VTE who also have thrombophilia. 10, 11 P20210 is determined only by DNA analysis because prothrombin activity does not adequately identify the presence of P20210. 19 
Deficiencies of Natural Anticoagulants
The inherited deficiencies of AT, PC, and PS account for only 1% to 5% of all patients with VTE. 20 All are caused by a large number of different mutations and are inherited in an autosomal dominant manner with variable penetrance. The peak presentation with a first thrombotic event is early, between 15 and 35 years of age. 21 Laboratory evaluation includes functional and antigenic assays; it is extremely important to exclude an acquired deficiency and to consider different analytic variables that can affect results ❚Table 1❚. [10] [11] [12] The risk of VTE in heterozygous AT deficiency is increased 5-to 50-fold compared with the general population. 11 There is a 50% risk of VTE developing during a patient's lifetime or during pregnancy. 22 Diagnosis of quantitative (type I) or qualitative (type II) deficiency 11, 21, [23] [24] [25] can be made with an algorithmic approach. 21 Clinical circumstances that suggest a laboratory evaluation for thrombophilia
Physical exam and complete medical history to evaluate for presence of acquired risk factors for thrombosis (see text)
Thrombophilia: High Priority Tests The best time to evaluate a patient for an inherited thrombophilia is in the outpatient setting after the acute thrombotic episode has resolved and the patient is no longer acutely ill. If thrombophilia testing must be done during a thrombotic event or anticoagulation, a number of assays may be affected depending on the patient's condition and the drug used. ❚Figure 1❚ Outline of the clinical circumstances that suggest a thrombophilia laboratory evaluation and the high priority screening tests. aCL, anticardiolipin antibodies; APCR, activated protein C resistance assay; APS, antiphospholipid syndrome; AT, antithrombin; β 2 GP1, β 2 -glycoprotein-1; FVL, factor V Leiden; HRT, hormone replacement therapy; LA, lupus anticoagulant; PC, protein C; PS, protein S; PT, prothrombin time; PTT, partial thromboplastin time; TT, thrombin time; VTE, venous thromboembolism.
Global coagulation tests
PC deficiency accounts for 2.5% to 5% of unselected patients with a first VTE. 7 Heterozygous deficiency increases VTE risk by 7-fold and carries an increased risk for warfarin-induced skin necrosis. 11 Homozygous deficient newborns have purpura fulminans; replacement therapy and anticoagulation are required for survival. However, there have been reports of patients with homozygous PC deficiency with a milder clinical course. 26 Quantitative and qualitative PC deficiency can be diagnosed by using an algorithm. 27 Acquired conditions that decrease PC activity must be excluded (Table 1) before making a diagnosis of inherited deficiency.
Laboratory investigation of PS deficiency is more complex with 3 distinct assay types: PS activity (clot-based) measures function as a cofactor for APC; free PS is an immunologic measure of the unbound fraction; and total PS antigen quantifies free and bound PS. Each assay has its own drawbacks, and they must be interpreted together to accurately diagnose PS deficiency. Because PS activity secondarily measures APC-dependent anticoagulant activity, many variables must be considered before ordering and/or interpreting values.
Falsely low values are found in up to 10% to 15% of healthy people. 28 Free PS antigen is more reliable and diagnoses 95% to 99% of PS deficiencies. 29 Inherited PS deficiency occurs in 1% to 13% of thrombophilic patients with VTE. 11 Types I, II, and III do not differ in clinical manifestations or severity, 29 and a diagnostic algorithm for PS deficiency is shown in ❚Figure 2❚. 30 
Antiphospholipid Antibodies and Antiphospholipid Syndrome
There are 3 major types of antiphospholipid antibodies (APAs): LAs, anticardiolipin (aCL), and anti-β 2 -glycoprotein-1 (anti-β 2 GP1) antibodies. 11 While most experts believe that patients suspected of having APS must be evaluated for all APAs, some prefer to evaluate for LAs and aCLs or anti-β 2 GP1. 9,10 LAs prolong clotting times by binding to phospholipids and interfering with their ability to serve as an essential clotting surface. Because of heterogeneous antibody specificity, no single test is 100% sensitive; thus, 2 or more phospholipid-based screening tests must be used to detect LAs, often the combination of a low-concentration phospholipid PTT and dilute Russell viper venom time. 31 ❚Figure 3❚ shows an algorithm for detecting LAs. Enzyme-linked immunosorbent assay detection of aCLs and β 2 GP1 antibodies is more straightforward, but there is a lack of standardization (ie, the same patient may have different results depending on which commercial test is used).
The criteria for APS include a positive APA result on 2 or more occasions at least 12 weeks apart 32 plus 1 of the following clinical criteria: (1) arterial, venous, or small vessel thrombosis occurring in any tissue or organ (VTE is most common in the extremities, followed by axillary, retinal, hepatic, and cerebral venous sinus thrombosis); (2) unexplained fetal loss at or beyond the 10th week of gestation; (3) birth of a morphologically normal neonate before the 34th week because of eclampsia, preeclampsia, or placental insufficiency; or (4) 3 or more unexplained consecutive spontaneous abortions before the 10th week of gestation. VTE is the most common manifestation of APS, and LA is the strongest risk factor for thrombosis and pregnancy morbidity. 33 Pregnancy loss is at least 3 times more likely in women with positive aCL or LA results. 34, 35 Hyperhomocysteinemia Hyperhomocysteinemia is an established risk factor for atherosclerosis and may also be associated with an increased risk for thrombosis. 10 Acquired causes of hyperhomocysteinemia (eg, vitamin B 6 , vitamin B 12 , or folate deficiency; hypothyroidism) are therefore of interest as possible treatable risk factors. 36 However, studies have not shown that treating elevated homocysteine levels with vitamins will reduce the thrombotic risk. Severe hyperhomocysteinemia caused by cystathionine β-synthase deficiency manifests as early arterial and/or venous thrombosis, 37 but it is unclear if mild (homocysteine level, <30 mmol/L) or moderate (homocysteine level, 30-100 mmol/L) hyperhomocysteinemia is a thrombophilia risk. 38 Some authors suggest measuring plasma homocysteine levels after a 10-hour fast for primary thrombophilia evaluation, with genetic testing if the result is more than 100 mmol/L, while most do not require fasting before measuring homocysteine levels. 10 Table 1 . † This approach decreases the chance of a low protein S level due to acquired causes; however, it can miss the diagnosis of a qualitative type II deficiency (<5% of cases of protein S deficiency). For that reason, some experts begin with a protein S activity assay. ‡ The protein S activity assay has several problems; refer to the text for testing considerations. § Total protein S may help confirm the diagnosis and differentiate the type of protein S deficiency but cannot be relied on as the primary assay because some hereditary and acquired deficiencies may have normal antigen levels. PT, prothrombin time; PTT, partial thromboplastin time.
Elevated Factor VIII
Increased FVIII activity is associated with VTE risk 39 for an initial episode and for recurrence. 40 The prevalence of FVIII of more than 150 U/L is 20% to 25% in patients with VTE, but in some patients, this is simply consistent with an acute phase response. 41 Thus, FVIII testing should be delayed for 6 months or longer after a VTE and for at least 6 weeks postpartum. If FVIII activity is high, retesting in 3 to 6 months will confirm persistence.
When Should Laboratory Evaluation for Thrombophilia Be Initiated?
Time of testing, patient age, sex, liver function, hormonal status, pregnancy, and acute phase reaction are important preanalytic variables to consider before investigating for thrombophilia (Table 1) . Timing is critical; coexistent ongoing or early thrombosis and/or heparin and warfarin therapy muddy the laboratory interpretation. For example, heparin will decrease AT, and warfarin blocks synthesis of active PC and PS. The acute management of VTE is rarely influenced by the immediate demonstration of a specific defect. Thus, the laboratory investigation of thrombophilia should be delayed for 6 months after the acute thrombosis, and 3 to 4 weeks after discontinuation of warfarin. Kovacs and colleagues 42 argue that testing a patient during the acute thrombotic event is practical and useful as long as the results are interpreted appropriately and tests with abnormal results are repeated 3 months later.
Immediate testing for certain thrombophilias is more clearly indicated, eg, for initial heparin treatment of a patient with LA who has VTE. The LA often prolongs the patient's baseline PTT; if this is not documented before starting heparin therapy, the elevated PTT may lead to a false conclusion that the patient's anticoagulation is therapeutic, when in fact, it is impossible to ascertain if these were true deficiencies (and, thus, risk factors for recurrent VTE) or simply a consequence of ongoing clotting/anticoagulation. The clinical pathology consultation suggested APCR/FVL and P20210 testing and APS studies. The patient had APCR due to heterozygous FVL, but he did not have P20210. LA was present, but aCL was negative (anti-β 2 GP1 was not measured). Since the diagnosis of APS requires LA confirmation at least 12 weeks after initial diagnosis, this testing will be done at follow-up when the patient has not been taking warfarin for 3 to 4 weeks. Thus, the only definitive thrombophilia found was heterozygous FVL. VTE risk is compounded or even synergistic when several individual risk factors, whether inherited or acquired, are present. 10 A single genetic or acquired risk factor does not commonly lead to VTE. Our patient had never experienced a VTE despite the presence of FVL until he acquired a "second hit" of trauma/surgery/anesthesia/immobilization. This VTE episode was clearly associated with his transient conditions. Despite his underlying inherited predisposition to VTE, studies have not suggested a need for lifelong anticoagulation in this subset of patients. However, he has now acquired a new risk factor for recurrence, namely a previous VTE. In this setting, measurement of the D-dimer level following discontinuation of warfarin may assist in determining if there is a need for prolonged anticoagulation, especially since he is now known to have FVL.
subtherapeutic. In such cases, the anti-Xa assay must guide heparin therapy. 7 A second example is when patients are suspected of having VTE due to APS; immediate detection of an LA could require prolonged warfarin therapy to prevent recurrence. 43 In addition, a chromogenic factor X may be informative when the international normalized ratio is therapeutic, to confirm that the LA is not falsely increasing it. A third example is when hereditary AT deficiency is suspected because of a known family history. To ensure sufficient plasma AT to mediate effective heparin anticoagulation, AT should be measured with the anti-Xa assay. If the AT is low, AT concentrates allow achievement of a therapeutic anti-Xa level. Of note, the laboratory should confirm "inherited" AT deficiency diagnosed during an acute VTE or during heparin therapy by remeasuring the AT when the patient is no longer acutely ill.
Evaluation of pediatric patients for inherited thrombophilia has unique considerations. Pediatric reference ranges for plasma AT, PC, and PS must be used because the agerelated differences will affect interpretation of the results. 44 
Treatment Implications of Thrombophilia
Thrombophilic risk factors in the absence of clinical manifestations do not justify prophylactic anticoagulation. For FVL, the 1% to 2% annual risk of major bleeding from warfarin is greater than the yearly risk of thrombosis (<1%). However, heterozygous FVL persons should be treated prophylactically during exposure to hemostatic stressors (surgery, pregnancy, and prolonged immobilization). [44] [45] [46] Still, the presence of thrombophilia does not affect the type and/ or duration of VTE, as reviewed recently. 45 However, the awareness of thrombophilia should be taken into account in decisions about long-term anticoagulation. In some people, the risk of recurrence may be high enough to justify lifelong prophylaxis following an initial VTE event, but large studies have not identified which, if any, thrombophilic patient subsets are at greatest risk for recurrence. Furthermore, the interaction of transient risk factors for hypercoagulability (eg, pregnancy or immobilization) needs to be considered with inherited thrombophilia. Indeed, after a first VTE, FVL and P20210 do not confer an increased risk of VTE recurrence when they are found in isolation; thus, lifelong anticoagulation is not indicated unless other risk factors are present. 45 
Discussion
Despite the acute VTE and the vitamin K antagonist, our patient had PC and PS activity levels within the reference range; had either been decreased, it would have been
